Fideuram Intesa Sanpaolo Private Banking S.P.A. Has $1.74 Million Stock Holdings in Olema Pharmaceuticals, Inc. $OLMA

Fideuram Intesa Sanpaolo Private Banking S.P.A. boosted its stake in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) by 3,237.5% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 116,812 shares of the company’s stock after purchasing an additional 113,312 shares during the period. Fideuram Intesa Sanpaolo Private Banking S.P.A.’s holdings in Olema Pharmaceuticals were worth $1,742,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. EverSource Wealth Advisors LLC increased its holdings in shares of Olema Pharmaceuticals by 9,476.9% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,245 shares of the company’s stock worth $31,000 after buying an additional 1,232 shares in the last quarter. Torren Management LLC acquired a new stake in shares of Olema Pharmaceuticals during the 4th quarter valued at $44,000. Nisa Investment Advisors LLC boosted its holdings in shares of Olema Pharmaceuticals by 14.5% during the 4th quarter. Nisa Investment Advisors LLC now owns 3,764 shares of the company’s stock valued at $94,000 after acquiring an additional 477 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in Olema Pharmaceuticals by 44.1% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,822 shares of the company’s stock worth $96,000 after acquiring an additional 1,169 shares during the last quarter. Finally, Russell Investments Group Ltd. acquired a new position in Olema Pharmaceuticals in the 3rd quarter worth about $53,000. Institutional investors and hedge funds own 91.78% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have commented on the company. TD Cowen reiterated a “buy” rating on shares of Olema Pharmaceuticals in a research report on Monday, March 9th. Wolfe Research assumed coverage on Olema Pharmaceuticals in a report on Friday, March 27th. They set a “peer perform” rating on the stock. Guggenheim lowered their price objective on Olema Pharmaceuticals from $38.00 to $35.00 and set a “buy” rating for the company in a research note on Wednesday, May 13th. HC Wainwright reiterated a “buy” rating on shares of Olema Pharmaceuticals in a report on Friday, May 22nd. Finally, The Goldman Sachs Group cut their target price on shares of Olema Pharmaceuticals from $38.00 to $27.00 and set a “buy” rating on the stock in a research report on Wednesday, March 18th. Eleven equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Olema Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $44.10.

Olema Pharmaceuticals Price Performance

Shares of NASDAQ:OLMA opened at $12.64 on Friday. The company has a market capitalization of $1.10 billion, a price-to-earnings ratio of -6.26 and a beta of 2.00. The company has a debt-to-equity ratio of 0.01, a current ratio of 10.88 and a quick ratio of 10.88. The business’s 50-day moving average is $12.43 and its 200-day moving average is $18.77. Olema Pharmaceuticals, Inc. has a 1 year low of $4.37 and a 1 year high of $36.26.

Olema Pharmaceuticals (NASDAQ:OLMA) last released its earnings results on Tuesday, May 12th. The company reported ($0.52) EPS for the quarter, hitting the consensus estimate of ($0.52). Equities research analysts predict that Olema Pharmaceuticals, Inc. will post -2.22 earnings per share for the current year.

Olema Pharmaceuticals Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.